CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 568 enrolled
Drug / intervention
Ibuprofen 250 mg / Acetaminophen 500 mg +3 moredrug
Likely dose
Ibuprofen 250 mg / Acetaminophen 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02912650
NCT02912650Phase 3Completed

A Phase 3, Double-Blind, Randomized, Safety And Efficacy Study Comparing A Single Oral Dose Of Ibuprofen (IBU) 250 Mg/Acetaminophen (APAP) 500 Mg (Administered As Two Tablets Of IBU/APAP 125 Mg/250 Mg) To Each Active Drug Monocomponent Alone And To Placebo In The Treatment Of Post-Surgical Dental Pain

Pfizer·interventional·Posted Sep 23, 2016·Updated Aug 30, 2017

In Brief

A Phase 3 clinical trial evaluating Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, and 2 other interventions for Post-surgical Pain Following Extraction of Molar Teeth. Completed, enrolled 568 participants across 1 site.

Detailed Summary

This is a randomized, double blind, placebo-controlled, parallel group, single-center study in approximately 560 subjects to determine the overall analgesic efficacy and safety of a fixed-dose ibuprofen 250 mg / acetaminophen 500 mg formulation compared to ibuprofen 250 mg alone, acetaminophen 650 mg alone, and to placebo. Subjects will be healthy males and females aged 18-40 years, inclusive, who are experiencing post-operative pain following surgical extraction of 3 or more third molar teeth. Following extraction, subjects must experience, within 5 hours, post-surgical pain of at least moderate severity (on a 4-point categorical scale), confirmed by a Visual Analog Pain Severity Rating Scale (VAS PSR) of at least 50 mm on a 100 mm VAS PSR scale. Eligible subjects will be randomized to receive a single oral dose of study medication under double-blind conditions and then evaluated on site for 12 hours following administration of study medication. Subjects will provide self-ratings of pain severity and pain relief at various time points using categorical and numerical scales. Additionally, subjects will also evaluate the time to first perceptible relief and time to meaningful relief using a double stopwatch method. Finally, at 12 hours, subjects will complete a categorical Global Evaluation of the study medication. A review of any reported adverse events will also be completed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 23, 2016
Enrollment StartSep 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago

Interventions

Ibuprofen 250 mg / Acetaminophen 500 mgdrug

2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg

Ibuprofen 250 mgdrug

2 caplets of Ibuprofen 125 mg

Acetaminophen 650 mgdrug

2 tablets of Acetaminophen 325 mg

Placebodrug

2 caplets of Placebo